HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Mafham, M, Preiss, D
Μορφή:	Journal article
Έκδοση:	Elsevier 2018

Παρόμοια τεκμήρια

GLP-1 receptor agonists and cardiovascular outcome trials: An update
ανά: Eirini Andrikou, κ.ά.
Έκδοση: (2019-11-01)

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
ανά: Kristensen, SL, κ.ά.
Έκδοση: (2019)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
ανά: Mustafa Kılıçkap, κ.ά.
Έκδοση: (2021-02-01)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
ανά: Fatemeh Taktaz, κ.ά.
Έκδοση: (2024-07-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
ανά: Marta Seghieri, κ.ά.
Έκδοση: (2018-11-01)

Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis
ανά: Jinjing Wei, κ.ά.
Έκδοση: (2022-12-01)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
ανά: María Isabel del Olmo-Garcia, κ.ά.
Έκδοση: (2018-01-01)

Adverse effects of GLP – 1 Receptor Agonists
ανά: Anna Kasprzak, κ.ά.
Έκδοση: (2025-02-01)

GLP-1 Receptor Agonists and Kidney Protection
ανά: Eulalia Valentina Greco, κ.ά.
Έκδοση: (2019-05-01)

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
ανά: Haran K, κ.ά.
Έκδοση: (2024-11-01)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
ανά: Xin Zhao, κ.ά.
Έκδοση: (2021-08-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
ανά: Qiyuan Keith Liu
Έκδοση: (2024-07-01)

Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.
ανά: Qinghua Wang, κ.ά.
Έκδοση: (2010-09-01)

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
ανά: Collin Vandemark, κ.ά.
Έκδοση: (2023-02-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
ανά: Lisa M Neff, κ.ά.
Έκδοση: (2010-07-01)

Role and development of GLP-1 receptor agonists in the management of diabetes
ανά: Chee&nbsp;W Chia, κ.ά.
Έκδοση: (2009-05-01)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
ανά: Ben Jones, κ.ά.
Έκδοση: (2018-04-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
ανά: Rizvi AA, κ.ά.
Έκδοση: (2022-04-01)

GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms
ανά: Daiji Kawanami, κ.ά.
Έκδοση: (2020-06-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
ανά: Miodrag Janić, κ.ά.
Έκδοση: (2024-12-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
ανά: Joanna Wojda, κ.ά.
Έκδοση: (2025-02-01)

GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
ανά: Sydney S. Wilbon, κ.ά.
Έκδοση: (2023-12-01)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
ανά: Giulia Monti, κ.ά.
Έκδοση: (2022-06-01)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
ανά: Neff LM
Έκδοση: (2010-07-01)

GLP-1 receptor agonist as a modulator of innate immunity
ανά: Jun Chen, κ.ά.
Έκδοση: (2022-12-01)

GLP-1 receptor agonists and myocardial metabolism in atrial fibrillation
ανά: Jiani Zhong, κ.ά.
Έκδοση: (2024-05-01)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
ανά: Francis S. Willard, κ.ά.
Έκδοση: (2020-09-01)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
ανά: Sara Piccini, κ.ά.
Έκδοση: (2023-03-01)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
ανά: Gian Paolo Fadini, κ.ά.
Έκδοση: (2020-04-01)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
ανά: Daria Ja’arah, κ.ά.
Έκδοση: (2021-10-01)

GLP-1 receptor agonists—another promising therapy for Alport syndrome?
ανά: Jan Boeckhaus, κ.ά.
Έκδοση: (2025-03-01)

Advances in GLP-1 receptor agonists for pain treatment and their future potential
ανά: Yongtao He, κ.ά.
Έκδοση: (2025-02-01)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
ανά: Aleksandra Jaroń, κ.ά.
Έκδοση: (2024-08-01)

Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
ανά: Hong Shurui
Έκδοση: (2023-01-01)

A potentially serious adverse effect of GLP-1 receptor agonists
ανά: Jinmiao Lu, κ.ά.
Έκδοση: (2023-05-01)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
ανά: Haiyang Du, κ.ά.
Έκδοση: (2022-11-01)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
ανά: Jinmi Lee, κ.ά.
Έκδοση: (2012-08-01)

GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events
ανά: Aurélie Pahud de Mortanges, κ.ά.
Έκδοση: (2022-03-01)

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide
ανά: Karen Schneck, κ.ά.
Έκδοση: (2024-03-01)

The benefits of GLP1 receptors in cardiovascular diseases
ανά: Lamija Ferhatbegović, κ.ά.
Έκδοση: (2023-12-01)